VAL - Ticker AI Digest

ValiRx plc 📰 1
TradingFloor AI GO VIP Login

Digested News

Today's Catalysts (VAL) 1
VAL 08:54
ValiRx plc
Update on Evaluation Agreement with Stingray Bio
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 2
VAL 06:01
ValiRx plc
Licensing Agreement with Dominion Biotech Ltd
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
ValiRx Plc, a life sciences company focused on early-stage cancer therapeutics and womens health, announced a strategic licensing agreement between its subsidiary Inaphaea BioLabs and Dominion Biotech Ltd. The agreement grants Dominion exclusive rights to Inaphaeas PredictRx® platform, a personalized cancer screening service that uses Patient Derived Cells (PDCs) to determine optimal chemotherapy treatments for individual patients.
Key terms of the agreement include
Inaphaea receives 50% of global net revenues from the PredictRx service.
Shared ownership of any new PDCs developed.
Initial 2-year term with annual renewal, and a buyout option after 18 months based on trailing net revenue.
While initial revenues are expected to be modest, the deal is strategically significant, showcasing the commercial potential of ValiRxs platform and establishing future buyout value. Both CEOs highlighted the agreements importance in advancing precision oncology and improving patient outcomes by personalizing cancer treatment.
ValiRx continues to focus on translational drug development and monetizing its biobank through partnerships like this, reinforcing its commitment to bringing innovative science to clinical practice.
VAL 06:01
ValiRx plc
Collaboration Agreement with Voxcell BioInnovation
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
ValiRx Plc, a UK-based life science company focused on early-stage cancer therapeutics and womens health, announced a collaboration agreement with Canada-based VoxCell BioInnovation Inc. The partnership aims to develop and commercialize Triple Negative Breast Cancer (TNBC) in-vitro 3D tumor models using ValiRxs Patient Derived Cells (PDC) and VoxCells proprietary vascularized 3D tissue culture technology.
Under the agreement, three TNBC PDC models will be optimized and <mark style="background-color:yellow">test</mark>ed at ValiRxs subsidiary Inaphaea BioLabs, then transferred to VoxCell for further development into vascularized 3D models. The collaboration seeks to
1. **Accelerate drug screening**Create more predictive, human-like tumor tissues for testing ValiRxs Clx001 oncolytic peptide asset and other potential therapies.
2. **Support regulatory shifts**Align with the FDA’s move away from animal-based testing, leveraging non-animal models for drug development.
3. **Expand partnership**Lay the groundwork for future collaborations on other cancer indications, utilizing ValiRx’s PDC biorepository and VoxCell’s advanced tissue models.
Both companies emphasized the potential of this partnership to generate valuable data for drug efficacy, tumor penetration, and nano-formulated drug delivery, ultimately advancing precision cancer treatment. The agreement also highlights ValiRx’s strategy to expand market access for its PDC models and testing services through strategic partnerships.
**Key Contacts and Resources**
ValiRx management is accessible via an Interactive Investor hub for shareholder engagement.
Further information is available on ValiRx’s website and through designated financial and PR contacts.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 0
No items for this category on selected date.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 0
No items for this category on selected date.
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 1
VAL 08:54
ValiRx plc
Update on Evaluation Agreement with Stingray Bio
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 3
VAL 08:54
ValiRx plc
Update on Evaluation Agreement with Stingray Bio
VAL 06:01
ValiRx plc
Licensing Agreement with Dominion Biotech Ltd
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
ValiRx Plc, a life sciences company focused on early-stage cancer therapeutics and womens health, announced a strategic licensing agreement between its subsidiary Inaphaea BioLabs and Dominion Biotech Ltd. The agreement grants Dominion exclusive rights to Inaphaeas PredictRx® platform, a personalized cancer screening service that uses Patient Derived Cells (PDCs) to determine optimal chemotherapy treatments for individual patients.
Key terms of the agreement include
Inaphaea receives 50% of global net revenues from the PredictRx service.
Shared ownership of any new PDCs developed.
Initial 2-year term with annual renewal, and a buyout option after 18 months based on trailing net revenue.
While initial revenues are expected to be modest, the deal is strategically significant, showcasing the commercial potential of ValiRxs platform and establishing future buyout value. Both CEOs highlighted the agreements importance in advancing precision oncology and improving patient outcomes by personalizing cancer treatment.
ValiRx continues to focus on translational drug development and monetizing its biobank through partnerships like this, reinforcing its commitment to bringing innovative science to clinical practice.
VAL 06:01
ValiRx plc
Collaboration Agreement with Voxcell BioInnovation
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
ValiRx Plc, a UK-based life science company focused on early-stage cancer therapeutics and womens health, announced a collaboration agreement with Canada-based VoxCell BioInnovation Inc. The partnership aims to develop and commercialize Triple Negative Breast Cancer (TNBC) in-vitro 3D tumor models using ValiRxs Patient Derived Cells (PDC) and VoxCells proprietary vascularized 3D tissue culture technology.
Under the agreement, three TNBC PDC models will be optimized and <mark style="background-color:yellow">test</mark>ed at ValiRxs subsidiary Inaphaea BioLabs, then transferred to VoxCell for further development into vascularized 3D models. The collaboration seeks to
1. **Accelerate drug screening**Create more predictive, human-like tumor tissues for testing ValiRxs Clx001 oncolytic peptide asset and other potential therapies.
2. **Support regulatory shifts**Align with the FDA’s move away from animal-based testing, leveraging non-animal models for drug development.
3. **Expand partnership**Lay the groundwork for future collaborations on other cancer indications, utilizing ValiRx’s PDC biorepository and VoxCell’s advanced tissue models.
Both companies emphasized the potential of this partnership to generate valuable data for drug efficacy, tumor penetration, and nano-formulated drug delivery, ultimately advancing precision cancer treatment. The agreement also highlights ValiRx’s strategy to expand market access for its PDC models and testing services through strategic partnerships.
**Key Contacts and Resources**
ValiRx management is accessible via an Interactive Investor hub for shareholder engagement.
Further information is available on ValiRx’s website and through designated financial and PR contacts.

AI Crunch

Single-Ticker AI Crunch
VAL signal theatre built from scored market catalysts, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for ValiRx plc. It compresses bullish and bearish catalyst scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full VAL AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored catalyst row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for VAL on 2025-08-05.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
2265543
Enterprise Value
16090853
Public Float
43.59
Broker Target
6
Shares Out
742801072
Long Interest
100
Short Interest
-
Exchange
LSE
Currency Code
GBX
ISIN
GB00BLH13C52
Market
LSE - AIM
Sector
Health Care
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
2009-01-01
Earnings Date
2025-09-25
Net Debt
-1544124.0
Cash
1555986.0
EPS
-0.01
Net Income
-1915693.0
Revenue
49775.0
Enterprise Value
16090853
Trailing PE
-
Forward PE
-
Price Sales TTM
45.5157
Price Book MRQ
0.6564
EV Revenue
35.2267
EV EBITDA
-5.9991

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
25.2718
Institutions As Of
2026-01-08
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
1
Sale Director Dealing
0
Purchase TR1
9
Sale TR1
1
Broker Coverage Rows
0
Institution Holders Tracked
4
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

Today's Catalysts

1 live catalyst just hit VAL.

The headlines landing in Digested News are now framed here as today's catalyst tape. Scroll the tab rail to Digested News or jump there instantly below.
Live Tape Data 2025-08-05 AI Charts Landing View
Scroll the tab rail to Digested News any time, or use the jump button to land straight on today's tape.
1 Today
Catalyst Pulse
ValiRx plc has fresh news flow feeding the chart narrative.
08:54 Today's Catalyst Update on Evaluation Agreement with Stingray Bio
AI Charts Studio
VAL Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2025-08-05 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
TradingFloor AI Member Login
Indicators0
Technicals0
AI Forecast -38.33%
RSI Gauge
Price Change
AI Forecast